Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | METTL3 | Q86U44 | 2/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CTSL | P07711 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940759 | 1.00 | CYP1A2 (1.00) | CYP1A2METTL3ATMNPC1RAB9A | |
| SCHEMBL13561199 | 0.83 | CYP1A2 (0.71) | CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27596091 | 0.81 | CYP1A2 (0.68) | CYP1A2METTL3ATMSMN1; SMN2CTSL | |
| SCHEMBL9656144 | 0.78 | NPC1 (0.64) | CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9656138 | 0.78 | NPC1 (0.64) | CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21994249 | 0.76 | CYP1A2 (0.61) | CYP1A2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23794042 | 0.72 | METTL3 (0.82) | METTL3ATM | |
| SCHEMBL7099176 | 0.72 | — | — | |
| Acetophenone-Thiosemicarbazone SCHEMBL17666972 | 0.72 | METTL3 (1.00) | METTL3ATM | |
| Phenyl(Methyl)Thiosemicarbazone SCHEMBL757506 | 0.72 | METTL3 (1.00) | METTL3ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8318782-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | FUJIFILM CORPORATION (JP) | 2011-11-10 | — | — | US | disclosed |
| EP-1454903-B9 | Thiadiazoline derivatives for treating cancer | KYOWA HAKKO KIRIN CO LTD (JP) | 2011-10-05 | — | — | EP | disclosed |
| EP-2327702-A1 | Mitotic kinesin inhibitor | Kyowa Hakko Kirin Co., Ltd. (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-7902234-B2 | Thiadiazoline derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-03-08 | — | — | US | disclosed |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| US-7851635-B2 | Mitotic kinesin inhibitor | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-12-14 | — | — | US | disclosed |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-7425636-B2 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD (JP) | 2008-08-28 | — | — | US | disclosed |
| EP-1847534-A2 | Thiadiazoline derivative | Kyowa Hakko Kogyo Co., Ltd (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070213380-A1 | Thiadiazoline derivative | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-09-13 | — | — | US | disclosed |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KYOWA HAKKO KOGYO CO., LTD. OF TOKYO, JAPAN FUJI PHOTO FILM CO., LTD. KANAGAWA, JAPAN | 2007-07-05 | — | — | US | disclosed |
| US-20060074113-A1 | Thiadiazoline derivative | KYOWA KIRIN CO., LTD. (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-1616866-A1 | M-STAGE KINESIN INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
| EP-1454903-A1 | THIADIAZOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074113-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CYP1A2 1617/4885METTL3 2876/4885ATM 516/4885 |
| US-20070155804-A1 | Mitotic kinesin inhibitor | KIF15, KIF5A, KIF5B | CYP1A2 3886/4885METTL3 4203/4885ATM 648/4885 |
| US-20070213380-A1 | Thiadiazoline derivative | BRWD1, RB1, ARG2 | CYP1A2 1617/4885METTL3 2876/4885ATM 516/4885 |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | CYP1A2 1527/4885METTL3 4575/4885ATM 4407/4885 |
| US-20110004000-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | CYP1A2 3886/4885METTL3 4203/4885ATM 648/4885 |
| US-20100240716-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, WDR82, RB1 | CYP1A2 2038/4885METTL3 2787/4885ATM 651/4885 |
| US-20080207706-A1 | THIADIAZOLINE DERIVATIVE | BRWD1, RB1, ARG2 | CYP1A2 1617/4885METTL3 2876/4885ATM 516/4885 |
| US-20110275827-A1 | Mitotic Kinesin Inhibitor | KIF15, KIF5A, KIF5B | CYP1A2 3886/4885METTL3 4203/4885ATM 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.